skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 

Three things you need to know in the financial markets this morning from investment writer, Tony Cross.

Dunelm Group

There’s a trading update out from Dunelm Group [LON:DNLM] this morning and what has arguably become the star of UK mainstream retail continues to shine. Pent up demand following the COVID lockdown meant that July’s sales were up 59% on a year-on-year basis, with August sales rising by a more measured – but still impressive – 24%. Those figures are materially ahead of expectations but the business remains cautious over the longer term outlook, given the risk of further local or national lockdowns. Preliminary results are due next week.

Oxford Biomedica

Oxford Biomedica [LON:OXB] has this morning announced that it has signed an 18 month supply agreement with AstraZeneca for large-scale commercial manufacture of its COVID-19 vaccine candidate. AstraZeneca will pay Oxford Biomedica £15million upfront as a capacity reservation fee, with an expectation of additional revenues in excess of £35million until the end of 2021. The deal can be extended for a further 18 months if necessary. The note adds that ‘Oxford Biomedica does not expect any impact to the Group’s current partnerships or ability to secure and support additional new partnerships in the cell and gene therapy field’.


There’s a fairly long note out from Saga [LON:SAGA] this morning, tackling the company’s need to refinance. It flags the fact that an unsolicited bid for the company from US investors had been made at 33p a share, something which the company has already rejected. Saga’s former owner is putting up £100m, whilst a prospective cap raise of a further £150m will be launched around the time of the interim results announcement next week. Given the company only has a c. £150m market cap at present, that’s a significant fund raising exercise and one that the market will no doubt watch with interest.

Sign up for three quick facts and more with our Free Daily Digest newsletter, every weekday morning.

Become a better investor with SharePad Designed to give you the confidence to pick your own investments, Sharepad gives you access to a wealth of information on UK, US & European stocks. Find out more

Please note this article does not constitute investment advice. Investors are encouraged to do their own research beforehand or consult a professional advisor.

Tony Cross

Tony Cross

Tony Cross is a market commentator with over 15 years of experience, producing compelling, insightful copy for journalists and investors alike. Focusing on macroeconomics, UK blue chip equities and inter market analysis, Cross's commentary is well regarded for its clarity and ability to cut through the waffle. He has been quoted in publications as diverse as The Financial Times, The Times, The Guardian and The Sun. He has also been a regular guest on both Share Radio and TipTV.

Stocks in Focus

Here are some of the smaller companies we are following most closely. They all represent significant growth stories in our view. Our in-depth reports go into more detail on why we like them.


Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Trade Nation
Back To Top